Funding for translating novel drug targets into precision cancer therapies

Oncode Oncology Bridge Fund and other investors including Johnson & Johnson Innovation - JJDC, Inc, announce a €20 million financing to advance development of first-in-class, small molecule inhibitors for the treatment of cancer. The funding is for Flindr Therapeutics and will allow the company to translate their novel drug targets into precision therapies, with the ultimate goal of transforming the lives of patients with cancer.

Flindr Therapeutics (formerly known as Immagene) was founded in 2020, as a spin-out of the Netherlands Cancer Institute and Oncode Institute, with the aim of developing next-generation first-in-class small molecule therapeutics for the precision treatment of cancer. Based on seminal findings which emerged from the labs of Daniel Peeper and Christian Blank, Flindr Therapeutics embarked on a drug discovery campaign against novel targets in hard-to-treat tumor indications.

Daniel Peeper: "I am very excited about this investment in Flindr Therapeutics. Among other activities, it allows the company to advance its lead program - the development of a first-in-class small molecule inhibitor of RNF31. This protein was previously identified in my laboratory in a genome-wide screen for new cancer therapeutic targets. It is gratifying to witness this fundamental discovery translate into the development of a novel anticancer drug."

Congratulations to the entire Flindr team for their dedication and hard work, resulting in this important achievement!

Share this story

Support our science?